EZH2 and liver cancer: As shown in Figure 5, higher expression of HNRNPM (HR = 1.64, 95% CI: 1.16–2.32, and P = 0.0047), SNRPE (HR = 1.65, 95% CI: 1.16–2.35, and P = 0.005), RRS1 (HR = 1.57, 95% CI: 1.11–2.22, and P = 0.011), BOP1 (HR = 1.85, 95% CI: 1.31–2.62, and P = 0.00039), SNRPB (HR = 1.61, 95% CI: 1.13–2.28, and P = 0.0076), EZH2 (HR = 2.23, 95% CI: 1.56–3.19, and P = 6.8×10−6), and ILF3 (HR = 1.55, 95% CI: 1.07–2.24, and P = 0.02) were significantly associated with reduced survival period of patients with liver cancer.